Vivior and SwissLens establish collaboration for the development of personalized contact lenses
Both Swiss companies agreed to collaborate in the field of personalized multifocal soft contact lenses for presbyopia correction. The objective is to optimize the design in soft multifocal contact lenses by using the data generated by Vivior’s visual behavior monitor, the Vivior Monitor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191202005453/en/
“The cooperation with SwissLens represents another milestone for Vivior. With SwissLens we have an established Swiss company as a partner in the growing field of multifocal personalized contact lenses. Both cooperation partners pursue the goal of achieving better vision comfort for customers and patients and complement each other perfectly in terms of technology,” says Andreas Kelch, Sales & Marketing Manager Vision Care at Vivior.
“With Vivior's innovative monitoring system, we obtain objective measurement data of visual behavior that are still unknown today. As a manufacturer of individual lenses, we can incorporate this data into the development of innovative new multifocal lenses. We are pleased about the partnership and the possibly resulting optimized lens designs that should enable the wearer to see better in all areas of vision,” explains Pascal Blaser, Head of Sales and R&D leader at SwissLens.
About SwissLens
Since 1997, SwissLens in Prilly, near Lausanne (Switzerland), has been manufacturing individual contact lenses of the highest quality and distributing them to eye specialists in over 25 countries. Thanks to extensive research, patented and innovative manufacturing technologies, SwissLens is constantly developing its products and services.
About Vivior
Vivior is a Swiss digital health start-up founded in 2017 by a group of experienced eye care professionals. The company offers a novel wearable device – the Vivior Monitor – to objectively measure visual behavior prior to vision correction interventions. The system collects daily activity data from customers and patients, processes these data in the cloud, and analyzes the lifestyle patterns using machine-learning algorithms. This ground-breaking combination allows to understand better the needs of customers and patients and enables eye care professionals to offer optimal personalized solutions to them. In addition, Vivior develops personalized spectacle, contact and intraocular lenses for vision correction in collaboration with various partners. The goal is to achieve better vision comfort for customers and patients based on the data generated by the Vivior Monitor.
www.vivior.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005453/en/
Contact information
For more information, please contact:
Vivior AG
Mario Stark, CEO
mario.stark@vivior.com
+41 79 542 88 74
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Launches AI Security Fabric, Providing AI Runtime Security for Agentic AI and LLM-Powered Applications11.12.2025 10:00:00 EET | Press release
AI is one of the fastest-growing technologies in the history of modern business, with the ability to revolutionize industries, optimize operations, and drive innovation, but it is also introducing security gaps, risks, and vulnerabilities. According to McKinsey, 78% of organizations are using AI in at least one business function, up from 55% two years ago. As a result, 73% of them are investing in AI-specific security tools, either with new or existing budgets, according to the 2025 Thales Data Threat Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211710650/en/ Thales AI Security Fabric Thales is introducing the first foundational capabilities of its AI Security Fabric to protect the core and edge of enterprises' AI ecosystems. Thales AI Security Fabric – Safeguarding LLM-Powered Apps, Data, and Identities With Thales AI Security Fabric, organizations will be able to: Unlock AI-driven growth securely: Maximize AI’
Interactive Brokers Adds Access to Brazil’s B3 Exchange11.12.2025 10:00:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that eligible clients outside of Brazil can now trade Brazilian equities through B3, the Brazil Stock Exchange. This expansion gives investors more ways to access emerging market opportunities across Latin America alongside global stocks, options, futures, currencies, bonds, funds, and more through a single unified platform. The B3 Exchange is one of the most active and liquid markets in the region. With this addition, investors will have direct access to trade Brazilian equities, plus over 160 markets worldwide using Interactive Brokers’ powerful trading platforms and tools. “Global investors need seamless access to diverse markets to stay competitive,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “By adding Brazil’s B3 Exchange, we’re giving our clients efficient, low-cost access to one of the world’s most dynamic emerging economies through our unified global platform.” Int
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman11.12.2025 09:30:00 EET | Press release
Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman. In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mullick to gain greater insights and understanding of the Japanese company, as the first non-Japanese CEO in the company’s long history. By reverting to the single leader model under Mullick in 2026, Kyowa Kirin aims
Tosi solmi merkittävän sopimuksen johtavan midstream-yhtiön EPIC Cruden kanssa11.12.2025 09:07:00 EET | Tiedote
OT-kyberturvallisuusalustojen globaali johtaja Tosi vahvistaa toimintaansa Yhdysvalloissa, ja yhtiö on solminut merkittävän tilaussopimuksen raakaöljyn kuljetuspalveluja tarjoavan johtavan midstream-toimijan EPIC Cruden kanssa. Aiemmin tänä vuonna solmittu arvoltaan kuusinumeroinen tilaussopimus on Tosin historian suurin. Sopimus vahvistaa merkittävästi Tosin asemaa öljy- ja kaasuteollisuudessa. Sopimus kattaa OT-verkkoinfrastruktuurin kokonaisvaltaisen korvaamisen uudella ratkaisulla sekä jatkuvan ylläpidon EPIC Cruden laaja-alaisissa toiminnoissa. EPIC Crudella on eri puolilla Texasia putkistoa 800 mailin pituudelta yhdistäen Delawaren, Midlandin ja Eagle Fordin öljykentät Meksikonlahden markkinoihin. EPIC Crude valitsi liiketoimintansa muuttuessa Tosin toimittamaan nopean, skaalautuvan ja kustannustehokkaan ratkaisun yhtiön nykyisen kuitupohjaisen verkon tilalle. Ennen käyttöönottoa Tosin tiimi perehtyi konsultoivalla lähestymistavalla EPIC Cruden liiketoimintavaatimuksiin. Tältä po
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin11.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210261871/en/ CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause.1 It is a common condition and prevalent in nearly 30% of the elderly in certain populations, but despite its debilitating impact – with effects on sleep, mental health, and overall quality of life – there are currently no approved treatments.1,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom